UK Scientists Report Successful Testing of Aradigm Corporation (ARDM)'s Inhaled Liposomal Ciprofloxacin in Q Fever
9/20/2012 9:28:39 AM
HAYWARD, Calif.--(BUSINESS WIRE)--UK scientists from the Health Protection Agency (HPA) and Defence Science and Technology Laboratory (Dstl) reported this week at the University of Southampton’s Wessex Life Sciences Alliance Conference the successful testing of Aradigm’s inhaled liposomal ciprofloxacin against Coxiella burnetii in a mouse model of this virulent infection. This work was conducted as part of the collaborative consortium that Aradigm Corporation formed with HPA and Dstl to evaluate the efficacy of Aradigm’s inhaled liposomal ciprofloxacin against high threat microbial agents.
comments powered by